Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics ...

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...

October 07, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.

Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV ...